Login to Your Account

AIDS Controversy Alive As Before; This Time, Phase III Data And Race

By Randall Osborne

Monday, March 10, 2003

Talk about a hard call.

Investors may have been quick to attach their unmistakable meaning to last month's disclosure by VaxGen Inc. of disappointing Phase III results for its HIV vaccine - the company's stock value nosedived by 47.3 percent - but the scientific world was far from convinced a disaster had taken place.

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription